[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608360":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":37,"centralContacts":42,"locations":51,"responsibleParty":74,"collaborators":30,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":30,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":30,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":54,"whyStopped":30,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"University of Oklahoma","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard of Care (Acetaminophen\u002FIbuprofen)","ACTIVE_COMPARATOR","This randomized control group will take a mandatory one-time dose of 500 mg acetaminophen with alternating 200 mg ibuprofen and 500 mg acetaminophen (standard of care) every 3 hours for pain.",[13],"Drug: Acetaminophen 500mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Meloxicam 7.5 mg","EXPERIMENTAL","This randomly assigned experimental group will take a mandatory one-time dose of oral Meloxicam 7.5 mg with as-needed acetaminophen 500 mg every 3 hours. Administration of Meloxicam will be upon completion of Mohs closure.",[19],"Drug: Meloxicam 7.5 mg",{"label":21,"type":16,"description":22,"interventionNames":23},"Meloxicam 15 mg","This randomly assigned experimental group will take a mandatory one-time dose of oral Meloxicam 15 mg with as-needed acetaminophen 500 mg every 3 hours. Administration of Meloxicam will be upon completion of Mohs closure.",[24],"Drug: Meloxicam 15 mg",[26,31,34],{"type":27,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","This intervention is the mandatory oral Meloxicam 7.5mg dose after Mohs closure.",[15],null,{"type":27,"name":21,"description":32,"armGroupLabels":33,"otherNames":30},"This intervention is the mandatory oral Meloxicam 15mg dose after Mohs closure.",[21],{"type":27,"name":35,"description":11,"armGroupLabels":36,"otherNames":30},"Acetaminophen 500mg",[9],[38],{"name":39,"affiliation":40,"role":41},"Lindsey Collins, MD","University of Oklahoma, Department of Dermatology","PRINCIPAL_INVESTIGATOR",[43,48],{"name":44,"role":45,"phone":46,"phoneExt":30,"email":47},"Chase Pitchford, MD","CONTACT","405-271-6110","chase-pitchford@ouhsc.edu",{"name":49,"role":45,"phone":46,"phoneExt":30,"email":50},"Landon Hendrickson, MD","Landon-Hendrickson@ou.edu",[52],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"University of Oklahoma Health Sciences Center","RECRUITING","Oklahoma City","Oklahoma","73104","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-97.51643,35.46756,{"lat":64,"lon":63},[67,70,73],{"name":68,"role":45,"phone":46,"phoneExt":30,"email":69},"Chase Pitchford","Chase-Pitchford@ouhsc.edu",{"name":71,"role":45,"phone":46,"phoneExt":30,"email":72},"Lindsey Collins","Lindsey-Collins@ouhsc.edu",{"name":39,"role":41,"phone":30,"phoneExt":30,"email":30},{"type":75,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100608360","phase-4-meloxicam-in-mohs-micrographic-surgery-100608360",false,"NCT07200544","Meloxicam in Mohs Micrographic Surgery","Meloxicam for Postoperative Pain in Mohs Micrographic Surgery","Inclusion Criteria:\n\n* All adult patients who consents to the study and are undergoing Mohs micrographic surgery at the University of Oklahoma.\n\nExclusion Criteria:\n\n* Women who are pregnant, suspected to be pregnant, or planning to become pregnant during the study period will be excluded from participation.\n* Chronic liver disease (chronic hepatitis, acute hepatitis, cirrhosis, NASH, NAFLD, alcoholic liver disease, hemochromatosis, Wilson's disease)\n* Chronic kidney disease stage III or greater,\n* Aspirin-sensitive asthma\n* History of chronic NSAID use\n* Patients vulnerable to drug interactions\n* GI bleeds\n* Peptic ulcers\n* Non-English speakers","ALL","18 Years","110 Years",{"count":87,"type":88},300,"ESTIMATED","INTERVENTIONAL",[91],"PHASE4","The goal of this clinical trial is to explore alternative methods of postoperative pain control in Mohs micrographic surgery. The main aims are:\n\n* To provide more information to the Mohs surgery community regarding postoperative pain control.\n* Reducing pain improves the overall comfort and well-being of patients, leading to a better post-operative experience.\n* To provide patients with an alternative and potentially superior NSAID for pain control (compared to standard-of-care ibuprofen).\n\nResearchers will compare 1) a single of dose Meloxicam 7.5 mg, followed by acetaminophen 500 mg; 2) a single dose of Meloxicam 15 mg, followed by acetaminophen 500 mg; 3) a single dose of acetaminophen 500 mg, followed by alternating ibuprofen 200 mg and acetaminophen 500 mg to see which better moderate pain control and patient satisfaction.\n\nParticipants will be asked to complete pain and patient satisfaction surveys.",[94,95],"Postoperative Pain, Acute","Skin Cancer",[97,98,99,100],"Mohs micrographic surgery","Postoperative Pain","NSAID","Acetaminophen","2025-12-09",{"date":103,"type":104},"2025-12-15","ACTUAL",{"date":106,"type":104},"2025-10-15",{"date":108,"type":88},"2026-08-02",{"name":5,"class":6},1]